Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). Retinoblastoma is a cancer that starts in the retina, the very back part of the eye. It is the most common type of eye cancer in children. During the early stages of development, the eyes have cells called retinoblasts that divide into new cells and fill the retina. At a certain point, these cells stop dividing and develop into mature retinal cells. Rarely, something goes wrong with this process. Instead of maturing into special cells that detect light, some retinoblasts continue to divide and grow out of control, forming a cancer known as retinoblastoma. Retinoblastoma starts with a mutation in a gene called the retinoblastoma (RB1) gene. Depending upon the changes in RB1 gene, retinoblastomas are two types, they are congenital (hereditary) retinoblastoma and sporadic (non-hereditary) retinoblastoma. Retinoblastoma is a rare disease. 9 in 10 children suffering from retinoblastoma are cured with the existing treatments.
Retinoblastoma Treatment Market: Drivers and Restraints
Retinoblastoma treatment market is driven by increasing remissions or recurrence of the disease and increasing awareness among healthcare professionals and patients. According to American Cancer Society, Inc. there are only about 200 to 300 children are diagnosed with retinoblastoma each year in the United States. Apart from aforementioned drivers, retinoblastoma market is driven by availability of better diagnostic tests and treatment options for the disease.
Request For Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-2783
Retinoblastoma treatment market hindered by the small patient pool for the treatment and stringent regulatory requirement for the approvals
Retinoblastoma Treatment Market: Segmentation
Retinoblastoma treatment market has been segmented on the basis of disease type, stage, treatment type, distribution channel and Region.
Based on the disease type, the global retinoblastoma treatment market is segmented into the following:
- Congenital (Hereditary) Retinoblastoma
- Sporadic (Non-Hereditary) Retinoblastoma
Based on the stage, the global retinoblastoma treatment market is segmented into the following:
- Intraocular Retinoblastoma
- Group A
- Group B
- Group C
- Group D
- Group E
- Extraocular Retinoblastoma
- Orbital Retinoblastomas
- Metastatic Retinoblastomas
Based on the treatment type, the global retinoblastoma treatment market is segmented into the following:
- Radiation Therapy
- Stem Cell Transplant
Based on the distribution channel, the global retinoblastoma treatment market is segmented into the following:
- Cancer Institutes
Retinoblastoma Treatment Market: Overview
Retinoblastoma treatment market is witnessing significant changes due to increasing opportunity for the pharmaceutical and medical devices companies to gain larger untapped market in developing and under developed economies. Companies’ continuously investing in developing newer treatment options for treating retinoblastoma.
Retinoblastoma Treatment Market: Region-wise Outlook
Geographically, global retinoblastoma treatment market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, Middle East and Africa. North America will remain key market for global retinoblastoma treatment market due to rising R&D activities by key players, better reimbursement policies, and availability of advanced healthcare infrastructure helps to maintain larger market share in the globalretinoblastoma treatmentmarket by the region. Asia Pacific is anticipated to present growth opportunity owing to large untapped market and growing government’s interventions for improving healthcare infrastructure in the region.
Visit For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-2783
Retinoblastoma Treatment Market: Key Players
Some of the players in the global retinoblastoma treatment market are Baxter, Bristol-Myers Squibb Company, GlaxoSmithKline plc., Spectrum Pharmaceuticals, Inc., CryoConcepts LP to name a few.